個案資料
了解個案內容與學習目標，選擇授課教師及使用課程。
Valeant's Battle for Allergan
內容大綱
On April 21, 2014 two companies, Valeant Pharmaceuticals and Pershing Square, announced an unsolicited merger offer for Allergan Pharmaceuticals. The unsolicited offer quickly turned into a hostile acquisition. The following months saw a raging public debate over the future control of Allergan and its primary product, Botox, as well as the business strategies and philosophies of the two offering firms and their CEOs.